Kornimate/medical-research-clean huggingface dataset:
choice of anesthesia for endovascular treatment of acute ischemic stroke in posterior circulation

Conditions: Posterior Circulation Brain Infarction

Summary: there is few randomized controlled clinical to investigated the impact of anesthetic type on outcome in patients with acute ischemic stroke in posterior cerebral circulation. it is unknown whether the choice of anesthesia is impacted on the outcomes for these patients or not. the investigators will perform a randomized controlled pilot clinical trial of general anesthesia versus local anesthesia/conscious sedation to explore and find out a potential fact whether anesthetic type alters perioperative neurological function in patients with acute ischemic stroke in posterior cerebral circulation.


Eligibility criteria:
inclusion criteria: * patients with acute ischemic stroke in posterior cerebral circulation scheduled to receive emergency endovascular treatment; age \> 18; the onset time is within 24 hours; modified rankin score ≤2 before onset. exclusion criteria: * radiological ambiguity concerning infarction and vessel occlusion; additional intracerebral hemorrhage; anterior circulation infraction; coma on admission (glasgow coma score less than 8); nihss less than 6 or more than 30; severe agitation or seizures on admission; obvious loss of airway protective reflexes and/or vomiting on admission; being intubated before treatment on admission; known allergy to anesthetic or analgesic;

Keywords: anesthesia methods acute ischemic stroke endovascular treatment
comparing reticulocyte hemoglobin and transferrin saturation to guide iron treatment in people on dialysis

Conditions: Hemodialysis; Anemia in End Stage Renal Disease

Summary: the goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (eskd) on hemodialysis who have anemia. the main questions it aims to answer are: can using reticulocyte hemoglobin equivalent (ret-he) to guide intravenous (iv) iron treatment be as effective as using transferrin saturation (tsat)? does the method used to guide iron treatment affect outcomes such as death, heart problems, hospitalizations, infections, or the need for blood transfusions? researchers will compare ret-he-guided iron treatment with tsat-guided iron treatment to see if ret-he works just as well and has similar or better outcomes. participants will: receive iv iron based on either ret-he or tsat levels have blood tests done at the start, 3 months, and 6 months have their doses of iron and erythropoietin (a medication to treat anemia) adjusted based on the assigned protocol be monitored for clinical outcomes such as hospitalization, heart events, and infections


Eligibility criteria:
inclusion criteria: * adult (age 18-80 years) * eskd on chronic hemodialysis ≥ 6 months * epo therapy ≥ 6 months * hb \< 13.0 g/dl in male, \< 12.0 g/dl in female exclusion criteria: * serum ferritin \> 800 ng/ml or tsat \> 40% * active infection or malignancy * hematologic disease including thalassemia major, hemolysis, myelofibrosis or myelodysplastic disease * history of marrow suppressive or immunosuppressive medications in past 6 months * history of active heart failure and recent myocardial infarction /stroke in past 6 months * history of gi or external bleeding or receiving blood transfusion in past 6 months

Keywords: reticulocyte hemoglobin equivalent transferrin saturation intravenous iron supplementation anemia in end stage renal disease hemodialysis
the effects of a music therapist designed listening program on intraoperative vitrectomy

Conditions: Pain, Postoperative; Music Therapy

Summary: this will be a prospective, randomized controlled trial with patients randomly assigned to either the experimental or control group. the experimental group will be exposed to the independent variable (iv) and the control group will not be exposed to the iv. the iv will be a music therapist- designed listening program during surgery. a total of 60 patients will be consecutively enrolled and undergo block randomization to either a music listening group or a control group (no music). trained medical research personnel will assist with various parts of the study and will be defined as those individuals who have completed and are up-to-date on the collaborative institutional training initiative (citi) training. these individuals will consist of a board certified music therapist, practicing ophthalmologists, and physicians-in-training.

this prospective trial will block randomize a consecutive cohort of patients undergoing routine vitrectomy surgery at an university hospital to a designed listening program during surgery or to nothing in order to determine whether music listening during surgery can measurably result in decreased patient pain assessed by the wong-baker faces pain scale. secondary outcome measures will be blood pressure, need for anxiety medication, postoperative pain medication, and patient overall experience.

Eligibility criteria:
inclusion criteria: * inclusion criteria will consist of patients already scheduled for elective vitrectomy surgery at a tertiary academic university hospital. exclusion criteria: * exclusion criteria consist of: patients with deafness or unilateral or bilateral severe hearing loss, unwillingness or inability to complete post-surgical surveys, previous vitrectomy surgeries, diagnosed anxiety disorder (claustrophobia, etc.), and/or chronic narcotic or substance abuse.
caudal bupivacaine vs bupivacaine plus two doses of dexmedetomidine for postoperative analgesia in children

Conditions: Pain, Postoperative

Summary: the aim of this prospective randomized double-blind study was to compare the analgesic efficacy and the side effects of two doses of dexmedetomidine (1 and 2 µg.kg-1) co-administered with bupivacaine with bupivacaine alone for caudal analgesia in children undergoing infra-umbilical surgery.

* quality assurance plan for data validation and registry: after data was registered, it was reviewed by a second person who compared it to the data in patient data collection forms. * data check: carried out using statistical package for the social sciences (spss) variable definition protocols. also data were entered in excel sheets for comparisons to guarantee consistency. * source data verification: paper case report forms and medical records. * standard operating procedures to address registry operations and analysis activities: eligible patients were recruited after obtaining consent. data was collected by qualified personnel rained on the process. data was entered into excel sheets and spss programs and compared for consistency. analysis of data was carried out by a qualified statistician. adverse events were reported as yes/no variables. data of patients who had change in management was omitted from analysis. * sample size assessment: sample size was calculated to detect a 65% reduction in the analgesic requirement during the first 24 h from 75% in the bupivacaine group with α= 0.05 and β=0.80. * plan for missing data: patients with missing data were omitted from statistical analysis. * statistical analysis plan: carried out using international business machines (ibm) statistics 19.0 statistical package for windows. data were compared using analysis of variance for continuous variables, kruskal-wallis test for ordinal, and chi square test for categorical ones. post hoc analyses were carried out as appropriate.

Eligibility criteria:
inclusion criteria: * patients with american society of anesthesiologists (asa) - i * scheduled for lower abdominal and perineal surgery * under general anesthesia exclusion criteria: * history of developmental delay or mental retardation * known or suspected coagulopathy or recent use of anticoagulant/antiplatelet drugs. * known allergy to any of the study drugs. * any signs of infection or congenital abnormalities at the site of the proposed caudal block

Keywords: caudal block
prevalence rate of pulmonary embolism among not anticoagulated patients

Conditions: Pulmonary Embolism

Summary: the purpose of this study is to evaluate the prevalence rate of pulmonary embolism among not anticoagulated patient older than 75 years old admitted with syncope and hospitalised in the toulon hospital

this study will be proposed to every patient that correspond to eligibility criteria. will be included only those who are not opposed to the collection of their data. the data collected will come from the routine care such as medical history, clinical datas, imaging data... the number of pulmonary imaging will be assessed before the diagnostic strategy proposed by dr prandoni and after the application of this strategy thanks to a questionnaire to physicians.

Eligibility criteria:
inclusion criteria: * male or female over 75 years-old * emergency consult resulting on an hospitalization in the geriatric service or in the internal medicine service * hospitalised in the centre hospitalier intercommunal de toulon for syncope, presenting these symptoms: * loss of consciousness with quick return to normal (less than one minute) * spontaneous resolution exclusion criteria: * history of syncope * other loss of consciousness (epilepsy, stroke, head trauma) * anticoagulated treatment * patient's objection
oral immunotherapy (oit) for peanut allergy

Conditions: Peanut Hypersensitivity

Summary: peanut allergy is known to cause severe anaphylactic reactions.the goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

peanut allergy is known to cause severe anaphylactic reactions. compared with other food allergies it tends to be more persistent and also its prevalence seems to be rising. currently there is no proven treatment other than strict avoidance. we are attempting to decrease the risk of anaphylaxis on accidental ingestion by desensitizing subjects to peanut using peanut oral immunotherapy (oit). we are also studying the effect of peanut oit on the peanut specific immune response to determine if tolerance to peanut protein will develop. children ages one to six years of age with peanut allergy will be randomized to peanut oit or placebo (active subjects). thirty subjects will also be recruited as controls. these subjects will not receive any peanut or placebo but only have skin prick testing and lab work in addition to a history and physical exam. active subjects will undergo a modified rush immunotherapy on the first day and then increase the doses at least every two weeks up to a maintenance dose of 4 grams (equivalent to about 13 peanuts). doses will be taken daily at home except for dose increases which will be done on the research unit. outcome variables of interest include response to double-blind placebo controlled food challenge, skin prick testing, peanut specific ige, and adverse events. these results will be compared between the start and end of peanut oit using appropriate statistical analysis.

Eligibility criteria:
inclusion criteria: * age 1- 6 years all of either sex, any race, any ethnicity at the time of the initial visit * the presence of ige specific to peanuts (a positive skin prick test to peanuts (diameter of wheal \>3.0 mm) and a positive in vitro ige \[cap-feia\] \> 7 kua/l * a history of significant clinical symptoms occurring within 60 minutes after ingesting peanuts * provide signed informed consent exclusion criteria: * history of severe anaphylaxis to peanut as defined by hypoxia, hypotension, or neurological compromise (cyanosis or oxygen saturation \< 92% at any stage, hypotension, confusion, collapse, loss of consciousness; or incontinence) * currently participating in a study using an investigational new drug * participation in any interventional study for the treatment of food allergy in the past 12 months * subjects with a known wheat food allergy will be excluded because of cross contamination of oat with wheat * poor control or persistent activation of atopic dermatitis * moderate to severe persistent asthma * currently being treated with greater than medium daily doses of inhaled corticosteroids, as defined by the national heart lung and blood institute (nhlbi) guidelines * inability to discontinue antihistamines for skin testing and oral food challenges (ofcs)

Keywords: peanut allergy
reduction efficacy of olomax for blood pressure and low-density lipoprotein cholesterol in hypertensive patients with dyslipidemia

Conditions: Hypertension; Dyslipidemias

Summary: this study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.

in this study, investigator will evaluate subjects' clinical performance in actual care. laboratory test results such as demographic information and medical treatment, blood pressure, blood lipid test, and liver function test conducted at the start date of olomax tablet administration and subsequent 24 weeks (± 8 weeks) will be collected. in the case of safety-related information, such as abnormal cases, data shall be collected at any time during the 24-week follow-up period if there is a visit by the study subject according to daily treatment.

Eligibility criteria:
inclusion criteria: 1. adult aged 19 or older at the time of the baseline visit. 2. a patient with hypertension and dyslipidemia who is scheduled to administer olomax tablet according to investigator's medical judgement. * patients who were previously taking more than two tablets of a single drug, low-density lipoprotein-cholesterol (ldl-c) * patients who were previously only taking blood pressure-lowering drugs and did not take ldl-c-lowering drugs, but who need to take additional ldl-c-lowering drugs at the discretion of the researcher * patients who were previously taking ldl-c lowering agents and did not take blood pressure lowering agents, but who need to take additional blood pressure lowering agents according to the researcher's judgment * patients who have not previously taken both a blood pressure drop and an ldl-c drop but need additional simultaneous use at the discretion of the researcher 3. a person who can understand the information provided to him/her and may voluntarily sign a written consent form exclusion criteria: 1. a person who falls under the prohibition of administration according to the permission for olomax tablet 2. a person who has a history of administering olomax tablets before participating in this study 3. in addition to the above, a person that the investigator thinks he/she is not suitable for participating in this observation study;
a study of intravenous (iv) mircera in hemodialysis patients with chronic renal anemia

Conditions: Anemia

Summary: this study will determine the appropriate dose and frequency of administration of iv mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin. the anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * chronic renal anemia; * on hemodialysis therapy for at least 3 months; * receiving iv epoetin alfa during the 2 weeks prior to the run-in period. exclusion criteria: * women who are pregnant, breastfeeding or using unreliable birth control methods; * use of any investigational drug within 30 days of the run-in phase, or during the run-in or study treatment period.
pilot trial of mobile technology for adolescent suicidality

Conditions: Suicidal Ideation

Summary: the primary objective of this study is to assess the efficacy of a digital intervention in reducing suicidal ideation in adolescents.

this double blind, randomized controlled trial will evaluate the preliminary efficacy of two digital interventions among 114 adolescent participants, and their parents/guardians, in reducing suicidal ideation in the adolescent participants. adolescent participants, parent/guardian participants, and research assessors will be blinded to treatment assignment.

Eligibility criteria:
inclusion criteria: 1. patients (of any sex), ages 13 to 17 years 2. patients who were recently hospitalized and have: 1. attempted suicide or 2. have documented si and a history of attempted suicide, as verified by the columbia-suicide severity rating scale (c-ssrs). hospitalized is defined as admission to a medical or psychiatric service for further assessment and care including observation units, intensive care or other medical units and psychiatric units. 3. patient owns a smartphone capable of downloading and running apps 4. patient is willing and able to complete enrollment procedures 5. patient and parent/guardian are willing to assent/consent to medical record review for one year following randomization to collect suicide attempt data 6. patient and parent/guardian are able to understand the nature of the study and sign documentation of written informed assent (patient) and consent (parent/guardian) 7. patient and parent/guardian understand written and spoken english 8. patient is willing to agree to release of information to their parent/guardian and providers when clinically indicated exclusion criteria: 1. patients who are acutely intoxicated or in detoxification at the time of enrollment 2. patients who are currently enrolled in other treatment studies for the symptoms and behaviors targeted 3. patients who are incapable of understanding and following through with the study procedures (e.g., cognitive impairment) 4. patients with a psychiatric or medical condition or custody arrangement that, in the opinion of the pi, may compromise, interfere, limit, affect or reduce the patient's ability to provide informed consent, complete the study, or may adversely impact the safety of the patient or the integrity of the data. examples of considerations include terminal illness where death would be anticipated before completing study procedures, active psychosis at the time of assent, severe or unstable medical condition. 5. patients whose discharge plans include transfer to inpatient care, as confirmed by the index hospitalization discharge summary/plan.
trauma registry in villavicencio, colombia

Conditions: Trauma; Trauma Blunt; Penetrating Wounds; Severe Trauma; Polytrauma; Registries

Summary: introduction: injuries are a leading cause of mortality worldwide. it is necessary to know the incidence of injuries, mechanisms of wounds, therapy provided, and outcomes. trauma registries are useful to describe the population served in specialized centers. nevertheless, it is necessary also to identify the peculiarities of the event in the province and institutions non-dedicated to trauma attention. objective: the study aims to describe the initial experience with a trauma register in a general hospital in the colombian orinoquia. methodology: the investigators designed an observational retrospective study to analyze the admission database and revision of history charts of patients older than 15 years admitted for trauma from january to june 2023 in a hospital from villavicencio, colombia. the information will be exported to excel for debugging and analysis. a description of the frequency and proportion of categorical variables will be performed; the central distribution and dispersion of quantitative variables will be reported. u of mann-whitney and chi-square tests will be used to compare the variables by outcome; a p\<0.05 was selected as a significant value. conclusions: it will be a pioneer study in this region, and it is necessary to evaluate the incidence of patients admitted by trauma, the mechanisms and type of injury, the care provided, and the outcomes.

trauma is a leading cause of global mortality or incapacitation in survivors. the population involved is mainly young adult men affected by preventable injuries. knowing the incidence of injuries, mechanisms of wounds, approaching strategies, and outcomes is essential to review individual interventions and collective policies to improve prevention. casualties in colombia had a high incidence in previous decades; injuries and attributable deaths have recently decreased, but they are still the third cause of mortality. contrary to high-income countries, interpersonal violence is the predominant mechanism involved. data registries are used worldwide in specialized centers that focus on providing healthcare in trauma. nevertheless, it is necessary also to know the incidence in community and non-dedicated general hospitals. determining the characteristics of patients admitted to the emergency ward by injuries will provide essential information on the severity, mechanisms, type of population affected, immediate or consequential care delivered, and outcomes. such an analysis will give knowledge to prioritize policies, resources, upgrade clinical practice guidelines, and improve results.

Eligibility criteria:
inclusion criteria: * patients admitted to the emergency ward by trauma. exclusion criteria: * none.

Keywords: wounds and injuries trauma severity indices trauma centers multiple trauma registries data collection routinely collected health data colombia
evaluating the safety of etanercept in the treatment of psoriasis in adult subjects

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate the safety and tolerability of long-term administration of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies. this study will also evaluate the maintenance of the efficacy of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies. all subjects enrolled in this study will receive 50 mg once weekly or twice weekly (if qualified after week 12) by subcutaneous injections for at least 48 weeks and up to 72 weeks.


Eligibility criteria:
inclusion criteria: - subjects who were randomized and received at least one dose of investigational product in study 20021639 or 20021642 (provided that they meet all inclusion/exclusion criteria of this protocol) exclusion criteria: * active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit * pregnant or breast-feeding females * evidence of skin conditions at the time of the screening visit (e.g., eczema) that would interfere with evaluations of the effect of the investigational product on psoriasis

Keywords: psoriasis, adults, skin phase 3, clinical trial amgen, etanercept enbrel®, moderate severe, extension
feasibility of total mastectomy in ambulatory care

Conditions: Breast Cancer; Mastectomy; Ambulatory Care

Summary: breast cancer is the first female cancer in france. total mastectomy occurred in 30% of breast cancer patient population. the purpose of this study is to evaluate the feasibility of outpatient surgery for the total mastectomy. in france, ambulatory care is developed as part of the new national health plan. breast conserving surgery for tumorectomy or partial mastectomy is already done in outpatient vacation. total mastectomy is an extension of this surgery, and, as such, underpins the investigator's hypothesis that total mastectomy is feasible in outpatient care .


Eligibility criteria:
inclusion criteria: * all patient with an indication of breast non conserving surgery exclusion criteria: * standard contra-indication for ambulatory care. * also bilateral surgery and immediate breast reconstruction.

Keywords: breast cancer mastectomy ambulatory care